Skip to main content
GenFleet Therapeutics (Shanghai) Inc. logo

GenFleet Therapeutics (Shanghai) Inc. — Investor Relations & Filings

Ticker · 2595 HKEX Manufacturing
Open in API
Filings indexed 667 across all filing types
Latest filing 2025-12-18 Proxy Solicitation & In…
Country HK Hong Kong
Listing HKEX 2595

About GenFleet Therapeutics (Shanghai) Inc.

http://www.genfleet.com

GenFleet Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies in oncology and immunology. Established in 2017, the company employs a "Global New" strategy centered on source innovation, targeting novel biological pathways and indications that have not yet achieved clinical validation to build a differentiated, high-value pipeline. GenFleet has demonstrated particular expertise in developing RAS-pathway targeted therapies. The company integrates international clinical and commercial development routes, utilizing global strategic cooperation to facilitate the future entry of its products into worldwide markets.

Recent filings

Filing Released Lang Actions
Form of Proxy for the Annual General Meeting to be held on Tuesday, 20 January 2026
Proxy Solicitation & Information Statement Classification · 1% confidence The document is explicitly titled 'FORM OF PROXY FOR THE ANNUAL GENERAL MEETING'. It provides instructions and a template for shareholders to appoint a proxy to vote on their behalf at the upcoming AGM. This falls under the category of Proxy Solicitation & Information Statement, which is used to request votes and provide meeting information to shareholders.
2025-12-18 English
(1) Renewal of General Mandates to Issue New Shares and Repurchase Shares&#x3b; (2) Re-election of Retiring Directors&#x3b; and (3) Notice of Annual General Meeting
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a circular issued by Water Oasis Group Limited to its shareholders. It contains formal proposals for the upcoming Annual General Meeting (AGM), specifically regarding the renewal of general mandates to issue and repurchase shares, the re-election of directors, and the notice of the AGM itself. This type of document is standard proxy solicitation material sent to shareholders to provide information and request votes for an upcoming meeting, which falls under the Proxy Solicitation & Information Statement category.
2025-12-18 English
Annual Report 2025
Annual Report Classification · 1% confidence The document is clearly identified as the '2025 Annual Report' for Water Oasis Group Limited. It contains comprehensive sections including the CEO's statement, Management Discussion and Analysis (MDA), corporate governance, and audited consolidated financial statements. It is a full-year report rather than an interim or quarterly update, and it is not a mere announcement of a report (RPA). FY 2025
2025-12-18 English
Final Dividend for the year ended 30 September 2025
Notice of Dividend Amount Classification · 1% confidence The document is a formal announcement from Water Oasis Group Limited regarding a 'Final Dividend' declaration. It specifies the dividend amount (HKD 0.025 per share), the ex-dividend date, record date, and payment date. This aligns perfectly with the definition for 'Notice of Dividend Amount' (DIV).
2025-12-15 English
Final Results Announcement For The Year Ended 30 September 2025
Annual Report Classification · 1% confidence The document is a 'Final Results Announcement' for Water Oasis Group Limited for the year ended 30 September 2025. It contains comprehensive audited financial statements, including the Consolidated Statement of Profit or Loss, Consolidated Statement of Financial Position, and detailed notes to the financial statements. While it is titled an 'announcement', it provides the full audited financial results for the fiscal year, which aligns with the definition of an Annual Report (10-K) in the context of HKEX-listed companies where the 'Final Results Announcement' serves as the primary annual financial disclosure document. FY 2025
2025-12-15 English
VOLUNTARY ANNOUNCEMENT First Site Initiated in a Registrational Study of GFH375 for Metastatic Pancreatic Cancer, as First-in-world Phase III Monotherapy Study of an Oral KRAS G12D Inhibitor versus Ch
Regulatory Filings Classification · 1% confidence The document is a 'Voluntary Announcement' issued by GenFleet Therapeutics regarding the initiation of a Phase III clinical trial for a drug candidate (GFH375). It provides business updates on clinical development progress, which does not fit into specific financial reporting categories like 10-K, IR, or ER. As it is a general regulatory announcement regarding company operations and clinical milestones, it falls under the 'Regulatory Filings' (RNS) category.
2025-12-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.